$VIGL News

Last published 1y ago

1y agoVIGLVigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSPGlobeNewswireWATERTOWN, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative
1y agoSNY VIGLVigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by SanofiGlobeNewswire- Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale
1y agoVIGLVigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business UpdatesGlobeNewswire– On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 – – Plans to initiate Phase 2 clinical trial evaluating VG-3927 in Alzheimer's disease in Q3 2025 –
1y agoVIGLVigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International ConferenceGlobeNewswire- Preclinical presentation highlights key, modality specific, pharmacological differentiations of VG-3927 - - First presentation of topline clinical data from Phase 1 SAD/MAD trial of VG-3927 for the potential treatment
1y agoVIGLVigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business UpdatesGlobeNewswire– Announced positive data from Phase 1 clinical trial evaluating VG-3927 for potential treatment of Alzheimer's Disease (AD); plans to initiate Phase 2 clinical trial in Q3 2025 – – On track to report final analysis
1y agoVIGLVigil Neuroscience to Present at the Stifel 2025 Virtual CNS ForumGlobeNewswireWATERTOWN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative
1y agoVIGLAugustine Therapeutics appoints Gerhard Koenig as Chief Executive Officer as Company Prepares to Enter the ClinicGlobeNewswireAugustine Therapeutics appoints Gerhard Koenigas Chief Executive Officer as Company Prepares to Enter the Clinic Industry veteran Gerhard Koenig, PhD, current Executive Chairman, appointed as CEOBest-in-class highly
1y agoVIGLVigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech ConferenceGlobeNewswireWATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative
1y agoVIGLVigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 MilestonesGlobeNewswire– On track to report data from Phase 1 clinical trial evaluating VG-3927 for the treatment of Alzheimer's disease in 1Q 2025 – – Final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP planned
1y agoVIGLVigil Neuroscience to Present at Upcoming Investor ConferencesGlobeNewswireWATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative
2y agoVIGLVigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire- Final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP planned for first half of 2025 - - Data from Phase 1 clinical trial evaluating VG-3927 in Alzheimer's Disease on track for first
2y agoVIGLVigil Neuroscience to Present at Guggenheim Healthcare Innovation ConferenceGlobeNewswireWATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative
2y agoVIGLVigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927GlobeNewswireWATERTOWN, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative
2y agoVIGLVigil Neuroscience to Present at Cantor Global Healthcare ConferenceGlobeNewswireWATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative
2y agoVIGLVigil Neuroscience to Present at Upcoming September Investor ConferencesGlobeNewswireWATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative
2y agoVIGLVigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire- Announced $40 million strategic investment from Sanofi; Extended cash runway into 2026 - - Provided update on iluzanebart clinical development strategy to pursue potential accelerated approval pathway in ALSP - -
2y agoVIGLVigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology GeneticsGlobeNewswire- CSF1R pathogenic and likely pathogenic variants reported to have an approximate prevalence of 281 per 1 million - - New research supports updated estimates to U.S. prevalence of approximately 19,000 and approximately
2y agoVIGLVigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)GlobeNewswire- First presentation of clinical data on sTREM2 from SAD cohorts in ongoing Phase 1 clinical trial of VG-3927 in healthy volunteers demonstrate proof-of-pharmacology - - New in vitro and in vivo data demonstrate the
2y agoVIGLVigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer's DiseaseGlobeNewswire- Safety, tolerability, pharmacokinetic and pharmacodynamic profile of VG-3927 supports continued development as potential once-daily oral therapy for Alzheimer's disease (AD) - - VG-3927 achieved robust decrease of
2y agoVIGLVigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International ConferenceGlobeNewswireWATERTOWN, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative
2y agoVIGLVigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSPGlobeNewswireWATERTOWN, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative
2y agoSNY VIGLVigil Neuroscience Announces $40 Million Strategic Investment from SanofiGlobeNewswire- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock- - Sanofi to receive an exclusive right of first negotiation for license of Company's small molecule TREM2 agonist program,
2y agoVIGLAugustine Therapeutics Raises EUR 17 Million in a Series A First Closing to Advance Lead Candidate Into Clinical Development in Neurological DiseasesBusiness WireProceeds will advance lead candidate AGT100216, a peripherally restricted and selective HDAC6 inhibitor, into a first-in-human clinical Phase 1/2 study Gerhard Koenig appointed as executive chairman of
2y agoVIGLVigil Neuroscience to Present in Upcoming June Investor ConferencesGlobeNewswireWATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative
2y agoVIGLVigil Neuroscience to Present at The Citizens JMP Life Sciences ConferenceGlobeNewswireWATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative
2y agoVIGLVigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire– Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer trial evaluating VG-3927 for Alzheimer's disease ongoing; Interim data
2y agoVIGLVigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual MeetingGlobeNewswire- Findings from ILLUMINATE Natural History Study show that MRI and fluid biomarkers are emerging as key measures of ALSP pathophysiology - - Positive interim IGNITE Phase 2 data demonstrating iluzanebart (VGL101) as
2y agoVIGLVigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewswire– Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evaluating iluzanebart (VGL101) for treatment of ALSP – – Enrollment for IGNITE trial completed with 20 patients enrolled; Next data
2y agoVIGLVigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical OfficerGlobeNewswireWATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative
2y agoVIGLVigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual MeetingGlobeNewswireWATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative
2y agoVIGLVigil Neuroscience to Present at Stifel 2024 Virtual CNS DaysGlobeNewswireWATERTOWN, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative
2y agoVIGLVigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024GlobeNewswireWATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative
2y agoVIGLVigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024GlobeNewswirePoster highlights clinical overlap of ALSP and multiple sclerosis (MS) and details patients' barriers to genetic testing WATERTOWN, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a
2y agoVIGLVigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology ConferenceGlobeNewswireWATERTOWN, Mass. , Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative
2y agoVIGLVigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 MilestonesGlobeNewswire- On track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024 and Phase 2 results from IGNITE clinical trial evaluating iluzanebart in ALSP in Q3 2024 - - Extends projected cash runway into
2y agoVIGLVigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx ConferenceGlobeNewswireWATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative
2y agoVIGLVigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATEGlobeNewswire- Iluzanebart demonstrated favorable safety and tolerability, including no hematologic adverse events - - Clear CNS target engagement and downstream pharmacological activity at 20 mg/kg consistent with Phase 1 data;
3y agoVIGLVigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewswire– Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in ALSP on track for this quarter – – First participant dosed in Phase 1 study of VG-3927, the first and only small molecule TREM2
3y agoVIGLVigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer's DiseaseGlobeNewswireWATERTOWN, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative
3y agoVIGLVigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro SummitGlobeNewswireWATERTOWN, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative
3y agoVIGLVigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSPGlobeNewswireWATERTOWN, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative
3y agoVIGLVigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual MeetingGlobeNewswire- Complete Phase 1 data analysis demonstrated that VGL101 continued to have a favorable safety and tolerability profile and proof-of-target engagement in SAD/MAD cohorts up to 60 mg/kg - - On track to report 6-month
3y agoVIGLVigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist ProgramGlobeNewswire- Announced VG-3927 as lead candidate to enter clinical development for potential treatment of Alzheimer's Disease - - IND for VG-3927 now open; Phase 1 clinical trial in healthy volunteers allowed to proceed with
3y agoVIGLVigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare ConferenceGlobeNewswireWATERTOWN, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative
3y agoVIGLVigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewswire- Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in people living with ALSP expected in fourth quarter of 2023 - - Small molecule TREM2 agonist IND submission and initiation of Phase 1
3y agoVIGLVigil Neuroscience Appoints Christopher J. Silber, M.D. as Chief Medical OfficerGlobeNewswireWATERTOWN, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative
3y agoVIGLVigil Neuroscience to Present at 2023 Jefferies Global Healthcare ConferenceGlobeNewswireWATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative
3y agoVIGLVigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewswire- Partial clinical hold lifted by FDA on VGL101 - - Launched ALSPAware to provide access to no-cost genetic testing and counseling for ALSP - - Appointed distinguished biopharmaceutical industry leader, Samantha Budd
3y agoVIGLVigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of DirectorsGlobeNewswireWATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative
3y agoVIGLVigil Neuroscience Launches ALSPAware to Provide Access to No-cost Genetic Testing and Counseling for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)GlobeNewswire– New genetic testing initiative designed to enable improved patient diagnosis of ALSP, a devastating, rare genetic neurodegenerative disease – – Through ALSPAware, individuals and healthcare providers can now access